Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Gouty Arthritis
Conditions
Acute Gouty Arthritis
Trial Timeline
May 1, 2011 → Sep 1, 2012
NCT ID
NCT01356602About Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + Placebo
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + Placebo is a phase 3 stage product being developed by Novartis for Acute Gouty Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01356602. Target conditions include Acute Gouty Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01356602 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Gouty Arthritis